Emergent BioSolutions insider sale: 17,801 shares via 10b5-1 plan

Rhea-AI Filing Summary

Emergent BioSolutions (EBS) — Form 4 insider transaction. A director reported selling 17,801 shares of common stock on 11/10/2025 at a weighted average price of $10.54, with trade prices ranging from $10.33 to $10.79. The sale was executed under a Rule 10b5-1 trading plan dated August 11, 2025, established to cover tax obligations from RSUs that vested on October 2, 2025. Following the transaction, the reporting person beneficially owns 119,858 shares.

Insider Trade Summary

Net Seller: 17,801 shares ($187,623)

Net Sell 1 txn

Insider DeGolyer Donald W

Role Director

Sold 17,801 shs ($188K)

Type	Security	Shares	Price	Value
Sale	Common Stock	17,801	$10.54	$188K

Holdings After Transaction: Common Stock — 119,858 shares (Direct)

Footnotes (1)

1. Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2025. For reporting purposes, sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $10.33 - $10.79. The Company maintains a record of the transactions and copies will be provided upon request.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeGolyer Donald W

(Last) (First) (Middle)

300 PROFESSIONAL DR

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025	11/10/2025	S		17,801(1)	D	$10.54(2)	119,858	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2025.

2. For reporting purposes, sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $10.33 - $10.79. The Company maintains a record of the transactions and copies will be provided upon request.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Emergent BioSolutions (EBS) disclose in this Form 4?

A director sold 17,801 shares of common stock on 11/10/2025 at a weighted average price of $10.54.

Was the EBS insider sale under a Rule 10b5-1 plan?

Yes. The sale was pursuant to a Rule 10b5-1 trading plan dated August 11, 2025.

Why were the EBS shares sold by the insider?

The filing states the sale was to satisfy tax obligations related to RSUs that vested on October 2, 2025.

What price range did the EBS shares trade at for this sale?

The reported trades occurred between $10.33 and $10.79; the weighted average was $10.54.

How many EBS shares does the insider own after the sale?

Beneficial ownership after the transaction is 119,858 shares.

What is the insider’s relationship to Emergent BioSolutions (EBS)?

The reporting person is a Director of the company.